Replimune Group, Inc.

Replimune Group, Inc.

REPLNYSE / NASDAQHealthcareSmall cap

$19.07-$0.16 (-0.8%)

Last close · Data as of Nov 20, 2026

Market cap
$815.0M
P/E
-3.3x
EV / EBITDA
-3.3x
Revenue
$0.00
ROCE
-53.1%

This period includes a one-day price step on 31 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Replimune Group, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+67.0%
3M
+35.7%
6M
Hidden
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 31 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 31 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.16 (-0.8%) from $19.23 to $19.07 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in REPL, bought on each weekday since 2021.

News & filings

What Replimune Group filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 247 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 7.95 times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.
  • This period includes a one-day price step on 31 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.

Read moreShow less

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Sector
Healthcare
Shares outstanding
77.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$815.0M
P/E
-3.3x
P/B
2.0x
EV / EBITDA
-3.3x
52-week high
Hidden
52-week low
Hidden

Profitability

ROE
-59.5%
ROCE
-53.1%
ROIC
-49.6%
ROA
-44.9%

Growth

Revenue
$0.00
Net profit growth, 1Y
14.6%
Free cash flow
-$198.9M

Solvency

Current ratio
7.95
Debt / Equity
0.18
Debt / Assets
0.14
CFO / Net profit
0.78
Cash / Market cap
13.6%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Replimune Group, Inc. revenue and net profit by fiscal year
Replimune Group, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$118.0M
FY2023$0.00-$174.3M
FY2024$0.00-$215.8M
FY2025$0.00-$247.3M

Cash flows

FY2025: -$192.3M from operations, -$198.9M free after investment (dashed).

Replimune Group, Inc. operating and free cash flow by fiscal year
Replimune Group, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$82.2M-$84.5M
FY2023-$128.1M-$130.3M
FY2024-$185.5M-$191.1M
FY2025-$192.3M-$198.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$235.4M
Net profit
-$247.3M
Cash from operations
-$192.3M
Free cash flow
-$198.9M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$235.4M-$247.3M-$198.9M-59.5%—+14.6%

Monthly returns

Month-by-month returns of REPL across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$551.3M
Liabilities$135.5M
Equity$415.8M
Paid-in capital$1.4B
Retained earnings-$948.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; REPL highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

Not shown (no positive earnings and no EV / Sales): Replimune Group, Inc., ORIC Pharmaceuticals, Inc., LB Pharmaceuticals Inc, Sana Biotechnology, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Replimune Group, Inc.REPLthis company$815.0M-3.3x2.0x-59.5%-3.3x
Janux Therapeutics, Inc.JANX$839.1M-7.4x0.9x-11.9%-5.2x
ORIC Pharmaceuticals, Inc.ORIC$830.2M-6.4x2.2x-33.7%-5.6x
LB Pharmaceuticals IncLBRX$828.8M-32.9x2.8x-8.4%-19.4x
Amphastar Pharmaceuticals, Inc.AMPH$824.5M8.4x1.0x12.4%6.2x
Sana Biotechnology, Inc.SANA$823.7M-3.4x5.1x-151.8%-4.3x
Esperion Therapeutics, Inc.ESPR$805.8M——7.5%13.9x
Lumexa Imaging Holdings, Inc.LMRI$791.7M-16.8x1.4x-8.0%12.0x
Eton Pharmaceuticals, Inc.ETON$791.6M-172.1x30.3x-17.6%249.0x
Peer median—-7.4x2.2x-10.1%0.9x

Year-to-date ROI

REPL since 1 January, against earlier years.

Historical volatility

REPL's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$259.9M
Research and developmentResearch And Development$189.4M
Selling, general and administrativeSelling General And Administration$72.2M
Other operating expensesOther Operating Expenses-$1.8M
Total expensesTotal Expenses$259.9M
Pretax incomePretax Income-$246.8M

Learn while you research

Academy chapters picked for Replimune Group, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →